Moxifloxacina Oara (Moxifloxacin)

Moxifloxacina Oara is a fluoroquinolone antibiotic used to treat bacterial infections in the respiratory and skin pathways.

• Community‑acquired bacterial pneumonia: eradicates the causative pathogens and improves lung function.
• Acute bacterial sinusitis: reduces sinus inflammation and clears infection.
• Acute bacterial exacerbation of chronic bronchitis: shortens symptom duration and prevents complications.
• Complicated skin and skin‑structure infections: eliminates bacterial load and promotes wound healing.

• Moxifloxacin inhibits bacterial DNA gyrase and topoisomerase IV, enzymes essential for DNA replication and transcription. By blocking these targets, it prevents bacterial cell division and leads to bacterial death, providing a bactericidal effect against susceptible Gram‑positive and Gram‑negative organisms.

Moxifloxacina Oara may cause adverse reactions that vary in frequency and severity.

Common Side Effects

• Nausea: mild to moderate stomach upset.
• Diarrhea: loose stools, often self‑limiting.
• Headache: transient cranial discomfort.
• Dizziness: occasional sense of imbalance.
• Rash: mild skin erythema.

Serious or Rare Side Effects

• Tendon rupture: sudden pain and loss of function, especially in the Achilles.
• QT interval prolongation: potential cardiac arrhythmia.
• Severe hypersensitivity: anaphylaxis or Stevens‑Johnson syndrome.
• Clostridioides difficile colitis: severe diarrhea with abdominal pain.
• Hepatotoxicity: elevated liver enzymes or jaundice.

Before prescribing Moxifloxacina Oara, clinicians should consider several safety aspects.

• Tendon health: avoid use in patients with recent tendon injury or corticosteroid therapy.
• Cardiac risk: assess QT prolongation potential in patients with known arrhythmias.
• Renal function: adjust monitoring in severe renal impairment.
• Pregnancy and lactation: use only if benefits outweigh potential risks, as safety data are limited.
• Drug hypersensitivity: discontinue if signs of severe allergic reaction appear.
• Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Moxifloxacina Oara can affect or be affected by other medicines, requiring careful review.

Major Interactions (Avoid)

• Antacids containing aluminum or magnesium: reduce absorption of moxifloxacin.
• Warfarin: may increase anticoagulant effect and bleeding risk.
• Drugs that prolong QT interval (e.g., quinidine, haloperidol): heighten arrhythmia risk.

Moderate Interactions (Monitor Closely)

• Non‑steroidal anti‑inflammatory drugs (NSAIDs): may increase risk of central nervous system stimulation.
• Corticosteroids: combined use may raise tendon rupture risk.
• Theophylline: may elevate plasma concentrations, requiring dose adjustment.